• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SHC

    Sotera Health Company

    Subscribe to $SHC
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the Americas, Europe and Asia. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: soterahealth.com

    Recent Analyst Ratings for Sotera Health Company

    DatePrice TargetRatingAnalyst
    5/5/2025$17.00Neutral → Buy
    Goldman
    12/6/2024$14.00Neutral
    Goldman
    5/21/2024$13.00Neutral
    Piper Sandler
    4/3/2024$18.00 → $16.00Neutral → Buy
    Citigroup
    3/25/2024$15.00 → $15.50Hold → Buy
    Jefferies
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    6/26/2023$24.00Sector Weight → Overweight
    KeyBanc Capital Markets
    1/23/2023$6.00 → $18.00Underweight → Neutral
    JP Morgan
    1/11/2023$6.00 → $22.00Underweight → Overweight
    Barclays
    1/11/2023$25.00Peer Perform → Outperform
    Wolfe Research
    See more ratings

    Sotera Health Company Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sotera Health Reports First-Quarter 2025 Results

      Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("

      5/1/25 7:38:53 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Announces First-Quarter 2025 Earnings Release Date

      CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the first-quarter ended March 31, 2025 before the market opens on Thursday, May 1, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations.

      4/17/25 5:16:45 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Nelson Labs Launches Innovative Rapid Sterility Testing to Significantly Expedite Product Sterility Results

      SALT LAKE CITY, March 04, 2025 (GLOBE NEWSWIRE) -- Nelson Labs, a Sotera Health company and a global leader in microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries, now performs product-sterility testing through rapid microbiological methods (RMMs) at three laboratory sites located in the United States and Europe. Nelson Labs' testing solution is unique in that it supports a broad range of both medical devices and pharmaceutical products. This innovative approach broadens the scope of Rapid Sterility Testing—a field that has primarily focused on products with biological components or short shelf life—by providing a vers

      3/4/25 7:00:37 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results; Provides 2025 Outlook

      2024 net revenues increased 4.9% to $1.10 billion, compared to 2023; or 5.4% on a constant currency basis2024 net income of $44 million or $0.16 per diluted share, compared to 20232024 Adjusted EBITDA(1) increased 3.9% to $549 million, compared to 2023; or 4.6% on a constant currency basis2024 Adjusted EPS(1) of $0.70, a decrease of $0.02 per diluted share, compared to 2023Full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization so

      2/27/25 7:00:37 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Announces Fourth-Quarter and Full-Year 2024 Earnings Release Date

      CLEVELAND, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2024 before the market opens on Thursday, February 27, 2025. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from

      2/18/25 4:30:57 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Chairman and CEO Presents at 43rd Annual J.P. Morgan Healthcare Conference

      CLEVELAND, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is presenting today at the 43rd Annual J.P. Morgan Healthcare Conference. During the presentation, Chairman and CEO Michael B. Petras, Jr. will be providing an update on Sotera Health's business. "I am pleased to announce that Sotera Health delivered another year of top-line growth in 2024," said Mr. Petras. "We expect full-year revenues will be approximately $1.1 billion, representing growth of nearly 5% versus 2023 and more tha

      1/14/25 7:30:09 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      CLEVELAND, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 11:15 a.m. Eastern Time. Mr. Petras, Jon Lyons, Senior Vice President and CFO, and Jason Peterson, Vice President, Investor Relations and Treasurer, will participate in meetings with investors during the conference. A live webcast of Mr. Petras' presentation and accompanying m

      1/7/25 4:30:23 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

      CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders. Mr. Petrella has decades of

      1/6/25 4:30:38 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health to Share Next Chapter of Growth at 2024 Investor Day

      CLEVELAND, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, will hold an Investor Day in New York City where Sotera Health's management team will discuss the Company's strategic positioning and outline future growth plans. Management will take questions from a live audience during two question-and-answer sessions. "The management team is looking forward to the Company's inaugural Investor Day since going public in 2020," said Michael J. Petras, Jr., Chair and CEO. "During the past four years, we have achieved top- and bo

      11/20/24 9:00:13 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Reports Third-Quarter and Year-to-Date 2024 Results

      Q3 2024 net revenues of $285 million increased 8.5%, compared to Q3 2023Q3 2024 net income of $17 million or $0.06 per diluted share, compared to net loss of $14 million or $0.05 per diluted share in Q3 2023 Q3 2024 Adjusted EBITDA(1) of $146 million increased 9.0%, compared to Q3 2023Q3 2024 Adjusted EPS(1) of $0.17 increased $0.01 per diluted share, compared to Q3 2023Reaffirming 2024 Net Revenue and Adjusted EBITDA outlook ranges CLEVELAND, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry,

      11/5/24 7:00:03 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    Sotera Health Company SEC Filings

    See more
    • SEC Form DEFA14A filed by Sotera Health Company

      DEFA14A - Sotera Health Co (0001822479) (Filer)

      5/2/25 4:05:40 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 10-Q filed by Sotera Health Company

      10-Q - Sotera Health Co (0001822479) (Filer)

      5/1/25 4:05:19 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Sotera Health Co (0001822479) (Filer)

      5/1/25 7:45:45 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form DEFA14A filed by Sotera Health Company

      DEFA14A - Sotera Health Co (0001822479) (Filer)

      4/10/25 7:33:26 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form DEF 14A filed by Sotera Health Company

      DEF 14A - Sotera Health Co (0001822479) (Filer)

      4/10/25 7:32:02 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Company filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Sotera Health Co (0001822479) (Filer)

      4/4/25 7:31:40 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 10-K filed by Sotera Health Company

      10-K - Sotera Health Co (0001822479) (Filer)

      2/27/25 4:02:27 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Sotera Health Co (0001822479) (Filer)

      2/27/25 7:16:12 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Sotera Health Co (0001822479) (Filer)

      1/14/25 7:35:05 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Sotera Health Co (0001822479) (Filer)

      1/6/25 4:38:40 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    Sotera Health Company Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman & CEO Petras Michael B. Jr. covered exercise/tax liability with 100,849 shares and was granted 298,953 shares, increasing direct ownership by 30% to 868,603 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      3/4/25 9:49:47 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • President of Sterigenics Rutz Michael P covered exercise/tax liability with 13,284 shares and was granted 48,579 shares, increasing direct ownership by 7% to 576,815 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      3/4/25 8:38:48 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sr. Vice President, CFO Lyons Jonathan M. covered exercise/tax liability with 6,481 shares and was granted 97,159 shares, increasing direct ownership by 82% to 201,110 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      3/4/25 8:36:07 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • SVP, General Counsel and Sec. Dimitrief Alexander covered exercise/tax liability with 8,211 shares and was granted 56,053 shares, increasing direct ownership by 17% to 334,725 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      3/4/25 8:34:18 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Chairman & CEO Petras Michael B. Jr. covered exercise/tax liability with 29,250 shares, gifted 39,243 shares and received a gift of 39,243 shares, decreasing direct ownership by 4% to 670,499 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      11/22/24 5:50:42 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • President of Sterigenics Rutz Michael P covered exercise/tax liability with 2,889 shares, decreasing direct ownership by 0.53% to 541,520 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      11/22/24 5:27:34 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Chairman & CEO Petras Michael B. Jr. gifted 200,000 shares (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      9/12/24 4:18:50 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Director Warburg Pincus & Co. sold $225,450,000 worth of shares (15,000,000 units at $15.03) (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      9/9/24 7:13:41 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Director Warburg Pincus & Co. sold $225,450,000 worth of shares (15,000,000 units at $15.03) (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      9/9/24 7:13:13 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Director Gtcr Investment Xi Llc sold $150,300,000 worth of shares (10,000,000 units at $15.03) (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      9/9/24 5:36:42 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    Sotera Health Company Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    Sotera Health Company Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Sotera Health upgraded by Goldman with a new price target

      Goldman upgraded Sotera Health from Neutral to Buy and set a new price target of $17.00

      5/5/25 8:27:32 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Goldman initiated coverage on Sotera Health with a new price target

      Goldman initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $14.00

      12/6/24 8:14:45 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Piper Sandler initiated coverage on Sotera Health with a new price target

      Piper Sandler initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $13.00

      5/21/24 7:45:20 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health upgraded by Citigroup with a new price target

      Citigroup upgraded Sotera Health from Neutral to Buy and set a new price target of $16.00 from $18.00 previously

      4/3/24 7:50:18 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health upgraded by Jefferies with a new price target

      Jefferies upgraded Sotera Health from Hold to Buy and set a new price target of $15.50 from $15.00 previously

      3/25/24 8:48:34 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • KeyBanc Capital Markets resumed coverage on Sotera Health

      KeyBanc Capital Markets resumed coverage of Sotera Health with a rating of Sector Weight

      2/6/24 6:37:50 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health upgraded by KeyBanc Capital Markets with a new price target

      KeyBanc Capital Markets upgraded Sotera Health from Sector Weight to Overweight and set a new price target of $24.00

      6/26/23 7:39:29 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health upgraded by JP Morgan with a new price target

      JP Morgan upgraded Sotera Health from Underweight to Neutral and set a new price target of $18.00 from $6.00 previously

      1/23/23 7:28:19 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health upgraded by Barclays with a new price target

      Barclays upgraded Sotera Health from Underweight to Overweight and set a new price target of $22.00 from $6.00 previously

      1/11/23 8:05:28 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Sotera Health from Peer Perform to Outperform and set a new price target of $25.00

      1/11/23 8:03:37 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/14/24 4:51:55 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/14/24 4:50:09 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/12/24 5:53:58 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/4/24 1:53:53 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G filed by Sotera Health Company

      SC 13G - Sotera Health Co (0001822479) (Subject)

      9/13/24 5:31:16 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Sotera Health Company (Amendment)

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      2/11/22 4:19:00 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Sotera Health Co (0001822479) (Subject)

      2/12/21 5:15:58 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Sotera Health Co (0001822479) (Subject)

      2/12/21 4:25:57 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    Sotera Health Company Financials

    Live finance-specific insights

    See more
    • Sotera Health Reports First-Quarter 2025 Results

      Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("

      5/1/25 7:38:53 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Announces First-Quarter 2025 Earnings Release Date

      CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the first-quarter ended March 31, 2025 before the market opens on Thursday, May 1, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations.

      4/17/25 5:16:45 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results; Provides 2025 Outlook

      2024 net revenues increased 4.9% to $1.10 billion, compared to 2023; or 5.4% on a constant currency basis2024 net income of $44 million or $0.16 per diluted share, compared to 20232024 Adjusted EBITDA(1) increased 3.9% to $549 million, compared to 2023; or 4.6% on a constant currency basis2024 Adjusted EPS(1) of $0.70, a decrease of $0.02 per diluted share, compared to 2023Full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization so

      2/27/25 7:00:37 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Announces Fourth-Quarter and Full-Year 2024 Earnings Release Date

      CLEVELAND, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2024 before the market opens on Thursday, February 27, 2025. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from

      2/18/25 4:30:57 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Reports Third-Quarter and Year-to-Date 2024 Results

      Q3 2024 net revenues of $285 million increased 8.5%, compared to Q3 2023Q3 2024 net income of $17 million or $0.06 per diluted share, compared to net loss of $14 million or $0.05 per diluted share in Q3 2023 Q3 2024 Adjusted EBITDA(1) of $146 million increased 9.0%, compared to Q3 2023Q3 2024 Adjusted EPS(1) of $0.17 increased $0.01 per diluted share, compared to Q3 2023Reaffirming 2024 Net Revenue and Adjusted EBITDA outlook ranges CLEVELAND, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry,

      11/5/24 7:00:03 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Announces Dates for Third-Quarter 2024 Earnings Release and November 2024 Investor Day

      CLEVELAND, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third-quarter ended September 30, 2024 before the market opens on Tuesday, November 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations.

      10/22/24 4:30:01 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Reports Second-Quarter and First-Half 2024 Results

      Q2 2024 net revenues of $277 million increased 8%, compared to Q2 2023Q2 2024 net income of $9 million or $0.03 per diluted share, compared to net income of $24 million or $0.08 per diluted share in Q2 2023Q2 2024 Adjusted EBITDA(1) of $137 million increased 7%, compared to Q2 2023Q2 2024 Adjusted EPS(1) of $0.19 declined $0.01 per diluted share, compared to Adjusted EPS of $0.20 in Q2 2023Successfully refinanced debt structure, extending debt maturities to 2031Reaffirming 2024 outlook CLEVELAND, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab test

      8/5/24 7:00:49 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Announces Second-Quarter 2024 Earnings Release Date

      CLEVELAND, July 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the second-quarter ended June 30, 2024 before the market opens on Monday, August 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations. A live

      7/22/24 5:00:19 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Reports First-Quarter 2024 Results

      Q1 2024 net revenues increased 12.5% to $248 million, compared to Q1 2023Q1 2024 net income of $6 million or $0.02 per diluted share, compared to net income of $3 million or $0.01 per diluted share in Q1 2023Q1 2024 Adjusted EBITDA(1) increased 13.7% to $112 million, compared to Q1 2023Q1 2024 Adjusted EPS(1) of $0.13 compared to Adjusted EPS of $0.13 in Q1 2023Company reaffirms 2024 outlook CLEVELAND, May 02, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the

      5/2/24 7:00:34 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Announces First-Quarter 2024 Earnings Release Date

      CLEVELAND, April 11, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the first-quarter ended March 31, 2024 before the market opens on Thursday, May 2, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations. A live

      4/11/24 4:00:43 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    Sotera Health Company Leadership Updates

    Live Leadership Updates

    See more
    • Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

      CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders. Mr. Petrella has decades of

      1/6/25 4:30:38 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Appoints Christopher Simon to the Board of Directors

      CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

      8/1/24 7:00:02 AM ET
      $HAE
      $SHC
      Medical/Dental Instruments
      Health Care
      Misc Health and Biotechnology Services
    • Sotera Health Appoints Karen Flynn to Board of Directors

      CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

      11/13/23 7:00:14 AM ET
      $CTLT
      $QTRX
      $SHC
      $WST
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Compass Diversified Announces New Leader for Healthcare Vertical

      WESTPORT, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE:CODI) ("CODI" or the "Company"), an owner of leading middle market businesses, today announced the appointment of Kurt Roth as Partner and Head of Healthcare for Compass Group Management LLC. In this role, Roth will work with the organization's senior investment professionals to launch CODI's new healthcare vertical. "Last December, we embarked on a journey to launch our third industry vertical," said Elias Sabo, CEO of Compass Diversified. "We chose healthcare as we believe it has multiple attractive, high-growth sectors with strong barriers to entry and advantageous demographic trends. Finding the right perso

      11/3/22 4:05:00 PM ET
      $CODI
      $SHC
      Home Furnishings
      Consumer Discretionary
      Misc Health and Biotechnology Services
      Health Care
    • Organogenesis Appoints Jon Giacomin to Board of Directors

      CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Jon Giacomin to the Company's Board of Directors, effective May 7, 2021. The Company also announced that Wayne Mackie resigned as a member of the Company's Board of Directors effective May 7, 2021. Mr. Mackie's resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices. "Jon is a proven leader who brings signifi

      5/10/21 7:30:00 AM ET
      $SHC
      $CAH
      $ORGO
      Misc Health and Biotechnology Services
      Health Care
      Other Pharmaceuticals
      Biotechnology: Pharmaceutical Preparations